PROCEPT BioRobotics: The Next Big Thing in Robotics

In the ever-evolving landscape of surgical robotics, one company stands out as a beacon of innovation and growth: procept biorobotics (PRCT). With a series of groundbreaking technological advancements and a relentless pursuit of market dominance, PROCEPT has positioned itself as one of the best robotics stocks to buy, according to billionaires and industry experts alike.



The company's recent financial performance speaks volumes about its potential. In the fourth quarter of 2024, PROCEPT reported total revenue of approximately $68.2 million, a staggering 57% increase compared to the prior year period. This growth was driven by increased system and handpiece sales, higher system average selling prices, and increased international revenue. For the full year 2024, revenue soared to $224.5 million, a 65% increase compared to 2023. These figures are a testament to the company's market traction and potential for future earnings.

But it's not just about the numbers. PROCEPT's recent technological advancements, particularly the HYDROS™ Robotic System, have positioned the company for future growth and competitive advantage. The HYDROS™ system represents the company's first significant technological advancement compared to the AquaBeam® system. This innovation is pivotal as it demonstrates PROCEPT's commitment to staying at the forefront of surgical robotics technology. The system's AI-driven technology and precise imaging capabilities set it apart from competitors, making it an attractive option for hospitals and surgical centers.

The HYDROS™ system's advanced features and capabilities give PROCEPT a competitive edge in the surgical robotics market. The system's AI-driven technology and precise imaging capabilities set it apart from competitors, making it an attractive option for hospitals and surgical centers. This competitive advantage is further supported by the company's strong financial performance, with a record gross margin of 63.2% in the third quarter of 2024.



When compared to other leading robotics companies in the market, such as intuitive surgical (ISRG) and boston scientific (BSX), PROCEPT BioRobotics stands out in terms of revenue growth and total return. For example, Intuitive Surgical reported a total return of 23.24% over the past 12 months, while Boston Scientific reported a total return of 45.07%. However, PROCEPT's revenue CAGR of 64.63% for the TTM is significantly higher than that of Intuitive Surgical and Boston Scientific, indicating that PROCEPT has a higher growth potential.

But the story doesn't end there. PROCEPT's focus on technological innovation aligns with its long-term vision to transform the global treatment of BPH and build a global urology company. The successful launch of the HYDROS™ system and the company's continued investment in research and development position it well for sustained growth and profitability in the future. As Reza Zadno, Chief Executive Officer, noted, "As we enter 2025, we believe there are several positive factors that will enable us to continue to pursue our long-term growth strategy while continuing a disciplined approach on our path to profitability."

In conclusion, PROCEPT BioRobotics (PRCT) is more than just a stock to buy—it's a company poised to revolutionize the surgical robotics industry. With its groundbreaking technological advancements, strong financial performance, and commitment to innovation, PROCEPT is a standout choice for investors looking to capitalize on the future of healthcare technology. As the company continues to push the boundaries of what's possible, it's clear that PROCEPT BioRobotics is one of the best robotics stocks to buy, according to billionaires and industry experts alike.

Ask Aime: What are the key factors driving PROCEPT BioRobotics' growth in the surgical robotics market?